Deprescribing as a Preventive Pharmacology Strategy

Abstract

Deprescribing has emerged as a critical preventive pharmacology strategy, especially in populations vulnerable to polypharmacy-related complications. This article synthesizes current evidence on deprescribing, emphasizing its role in optimizing pharmacotherapy, reducing adverse drug events, and improving patient outcomes. The review explores epidemiological trends, underlying mechanisms, risk factors for inappropriate prescribing, clinical features of polypharmacy, diagnostic approaches to medication review, and evidence-based deprescribing interventions. Recent advances, including digital health tools and updated international guidelines, are discussed alongside expert perspectives on implementation. The content targets clinicians seeking to incorporate deprescribing into patient-centered care, with practical implications for primary, geriatric, and chronic disease management.

Introduction

Pharmacotherapy remains fundamental to modern medicine, yet the increasing prevalence of polypharmacy and inappropriate medication use presents significant clinical challenges. Deprescribing, defined as the systematic process of identifying and discontinuing medications when existing or potential harms outweigh benefits, has gained recognition as an essential preventive strategy. The rationale for deprescribing is rooted in the growing body of evidence linking polypharmacy to adverse drug reactions, hospitalizations, functional decline, and mortality, particularly among older adults and those with multimorbidity. This comprehensive review aims to equip healthcare professionals with an in-depth understanding of deprescribing principles, evidence base, and practical approaches to implementation in routine clinical practice.

Epidemiology / Disease Burden

Polypharmacy, commonly defined as the use of five or more medications, affects up to 40% of adults over the age of 65 and is associated with increased morbidity and healthcare utilization. Inappropriate prescribing, including the use of potentially inappropriate medications (PIMs), is prevalent in both community and institutional settings. Epidemiological data from recent cohort studies highlight a direct correlation between polypharmacy and adverse clinical outcomes, such as falls, cognitive impairment, and hospital readmissions. The global burden is amplified by demographic shifts toward aging populations, increased prevalence of chronic diseases, and fragmented care transitions, underscoring the urgent need for preventive pharmacological strategies like deprescribing.

Pathophysiology

The pathophysiological basis for deprescribing as a preventive strategy lies in the interplay between age-related pharmacokinetic and pharmacodynamic changes, multimorbidity, and drug-drug interactions. Reduced renal and hepatic function, alterations in body composition, and receptor sensitivity contribute to increased susceptibility to adverse drug events (ADEs). Polypharmacy exacerbates these risks through cumulative anticholinergic, sedative, and antithrombotic effects. Mechanistically, deprescribing mitigates physiological and biochemical stressors by reducing medication burden, thereby restoring homeostasis and minimizing iatrogenic harm.

Risk Factors

Key risk factors for inappropriate medication use and polypharmacy include advanced age, multiple comorbidities, cognitive impairment, care fragmentation, and lack of regular medication review. Patients discharged from hospital, those receiving care from multiple prescribers, and individuals with limited health literacy are at highest risk. Social determinants, such as limited access to primary care and insufficient caregiver support, further compound the vulnerability to medication-related harm. Recognizing these risk factors enables targeted deprescribing interventions and individualized risk-benefit assessments.

Clinical Features

Clinically, the consequences of polypharmacy and inappropriate prescribing manifest as falls, delirium, orthostatic hypotension, gastrointestinal bleeding, renal dysfunction, and drug-induced cognitive impairment. Symptoms are often nonspecific and may be misattributed to aging or comorbidities. Deprescribing can lead to clinical improvements in mobility, cognition, quality of life, and functional status. Early identification of medication-related problems through comprehensive medication review and patient-centered assessment is crucial to guide safe deprescribing practices.

Diagnosis

Diagnosis of polypharmacy and medication-related harm relies on structured medication reconciliation, detailed history taking, and the use of explicit criteria such as the Beers Criteria, STOPP/START criteria, and Medication Appropriateness Index. Clinical pharmacists, primary care providers, and geriatricians play a pivotal role in evaluating drug regimens, identifying PIMs, assessing drug-drug and drug-disease interactions, and prioritizing medications for potential discontinuation. Diagnostic tools increasingly include electronic prescribing platforms and clinical decision support systems to facilitate safe and effective deprescribing.

Treatment & Management

The deprescribing process involves shared decision-making, individualized risk-benefit analysis, and a structured approach to medication withdrawal. Key steps include medication reconciliation, identification of goals of care, prioritization of medications for cessation, gradual dose reduction when appropriate, and close monitoring for withdrawal or disease recurrence. Multidisciplinary collaboration, patient engagement, and education are essential for successful deprescribing. Barriers such as patient resistance, provider inertia, and system-level constraints must be addressed through targeted interventions, education, and policy support.

Recent Advances / Emerging Therapies

Recent advances in deprescribing include the integration of digital health tools, such as computerized clinical decision support, to flag high-risk medications and guide evidence-based deprescribing pathways. Large-scale randomized controlled trials, such as the D-PRESCRIBE and OPTIMIZE studies, have demonstrated reductions in PIM use and improved clinical outcomes with structured deprescribing interventions. Emerging therapies focus on personalized medicine approaches, pharmacogenomic profiling, and the development of patient engagement platforms to support shared decision-making. International deprescribing networks and collaborative initiatives are advancing research, education, and guideline development in this field.

Guideline Recommendations

Multiple national and international guidelines now advocate regular medication review and deprescribing as core components of chronic disease management, particularly for older adults. Recommendations from bodies such as the American Geriatrics Society, NICE, and the Canadian Deprescribing Network emphasize the use of validated screening tools, interdisciplinary collaboration, and patient-centered care. Guidelines encourage clinicians to proactively assess the ongoing need for each medication, consider deprescribing in the context of changing health status or goals of care, and ensure adequate monitoring and follow-up during the deprescribing process.

Conclusion

Deprescribing represents a paradigm shift toward preventive pharmacology, prioritizing patient safety, quality of life, and optimal therapeutic outcomes. As evidence supporting deprescribing continues to grow, its integration into routine clinical practice is essential for mitigating the burden of polypharmacy and medication-related harm. Clinicians must leverage guideline-based approaches, multidisciplinary collaboration, and emerging digital health tools to implement effective deprescribing strategies tailored to individual patient needs. Ongoing research, education, and policy development will further enhance the reach and impact of deprescribing in contemporary healthcare.